Business Wire

New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer

Share

Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1

A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 and cisplatin 80mg/m2 D1 every 3 weeks.1

The primary endpoint for phase II was the overall response rate (ORR), measured in line with the RECIST 1.1 guidelines. The results showed a significant tumour shrinkage of 95.3% with an ORR of 76.7%. Of these patients, 16.3% exhibited complete response (CR) and 60.5% partial response (PR). Furthermore, PD-L1 status at diagnosis did not have an effect on overall survival (OS) and the data also indicate a disease control rate (DCR) of 97.7%.1

Secondary endpoints for the trial included progression-free survival (PFS), OS, duration of response (DoR) and safety. Molecular analysis was carried out through targeted next generation sequencing (NGS). The median PFS was 8.6 months (95% CI 7.2-16.4) and the median OS was 19.3 months (95% CI 16.5-NA).1 The median duration of response (DOR) was 10.8 months (95% CI 7.17-NA).

Whilst carrying out the study, the investigators did not observe any new safety signals. The most common haematologic adverse events included a decreased neutrophil count, as seen in 46.5% of patients, and anaemia which was experienced by 32.6%. Other frequently reported adverse events included anorexia (39.5%) and nausea (32.6%), and the most observed immune-related adverse event was hypothyroidism (11.6%).1

“According to our study, patients with HER2-positive AGC treated with this first-line triplet regimen experienced clinically meaningful improvements in tumour shrinkage regardless of PD-L1 status,” said Professor Sun Young Rha at Yonsei Cancer Center, Yonsei University College of Medicine. “Enabling access to the first immunotherapy/chemotherapy combination with Herzuma®(biosimilar trastuzumab) in the first-line setting will make a real difference to patients.”

Prof Rha added, “With the costs of oncology treatments being so burdensome, the availability of biosimilar trastuzumab could reduce the overall cost by combination treatment with innovative new drugs and chemotherapy. High quality treatments at reduced overall treatment cost could imply a benefit to health systems worldwide.”

-- ENDS --

Notes to Editors:

About metastatic (advanced) gastric cancer2,3,4,5

Gastric cancer is a leading cause of cancer-related deaths worldwide, with over a million new cases of gastric cancer diagnosed each year. HER2 overexpression has been reported in 7-34% of gastric cancers. Gastric cancer commonly begins in the inner lining of the upper part of the stomach and can spread through the walls of the stomach. The cancer can then invade other organs or spread to the lymph vessels and nodes. Gastric cancer can be staged from 0 to IV depending on its progression. As the stage number increases, the larger the cancer growth and the further the cancer has spread.

Clinical trials have evaluated trastuzumab in combination with chemotherapy as first-line treatment for metastatic (advanced) gastric cancer.

About Herzuma® (biosimilar trastuzumab)6

Herzuma® is a humanised monoclonal antibody that is designed to bind selectively to the extracellular domain of an antigen called human epidermal growth factor reception 2 (HER2). Herzuma® is indicated for the treatment of adult patients with early breast cancer, metastatic breast cancer, and metastatic gastric cancer and was approved by the European Medicines Agency (EMA) in February 2018.

Similarity of Herzuma® to the reference product, Herceptin® was demonstrated in terms of pharmacokinetic, pharmacodynamics, efficacy and safety through multiple global clinical trials.6

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

Forward Looking Statement

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References


1 Rha, S., Lee, C., Kim, H., et al. Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2 positive advanced gastric cancer (AGC). Poster presented at: ASCO20 Virtual Scientific Program; May 29, 2020
2 Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26‐38. doi:10.5114/pg.2018.80001
3 Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637‐650. doi:10.1038/modpathol.2011.198
4 Kanayama K, Imai H, Usugi E, Shiraishi T, Hirokawa YS, Watanabe M. Association of HER2 gene amplification and tumor progression in early gastric cancer. Virchows Arch. 2018;473(5):559‐565. doi:10.1007/s00428-018-2433-y
5 Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010 Oct 16;376(9749):1302]. Lancet. 2010;376(9742):687‐697. doi:10.1016/S0140-6736(10)61121-X
6 European Medicines Agency Summary of Product Characteristics (SmPC). Herzuma. Available at https://www.ema.europa.eu/en/documents/product-information/herzuma-epar-product-information_en.pdf Last accessed May 2020

Contact information

Zuzanna Grzeskiewicz
zgrzeskiewicz@hanovercomms.com
+44 (0)7506 339043

Sophia Eminson
seminson@hanovercomms.com
+44 (0)7751 116252

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RELX Outlines at the GTNF Role of Technology in Advancing Vaping Industry’s Responsible Practices21.9.2020 14:29:00 CESTPress release

The company’s Global External Affairs Lead provided concrete examples of how RELX has been harnessing the power of technology, innovation and research in its quest to forge ahead robust youth prevention mechanisms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005456/en/ Jonathan Ng speaking at the GTNF Innovations on the Horizon panel. (Photo: Business Wire) At the virtual Global Tobacco & Nicotine Forum (GTNF) event yesterday, RELX Technology’s Global Head of External Affairs Jonathan Ng spoke on a panel entitled “Innovations on the Horizon.” The panel explored several topics related to the growing international acceptance of e-cigarettes as better alternatives to cigarettes, innovations related to user experience and youth prevention, and illicit trade. GTNF is one of the leading tobacco and nicotine forums in the world; speakers and attendees include public health experts, government representatives, investors and

CHMP Grants Positive Opinion for Expanded Use of Otsuka’s Deltyba ® (delamanid) in Children and Adolescents Weighing at Least 30kg Treated for Pulmonary Multi-drug Resistant Tuberculosis21.9.2020 13:12:00 CESTPress release

Otsuka Novel Products GmbH (ONPG), a subsidiary of Otsuka Pharmaceutical Co., Ltd., is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of extension of the indication for Deltyba® (delamanid) for children. This means Deltyba® (delamanid) is recommended by the CHMP for use as part of an appropriate combination regimen for pulmonary MDR-TB in adults, adolescents and children with a body weight of at least 30kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. According to the current World Health Organization Global TB Report, an estimated 1.1 million children (0-14 years of age) fell ill with TB in 2018.2 Each year, approximately 25,000-32,000 children fall ill with MDR-TB. Of these, only 3-4% are diagnosed and treated and consequently, approximately 21% of children with MDR-TB are likely to die.1 New global targets set at the UNs High Le

Visa Helps Prepare Small Businesses for the Holiday Buying Season as National Small Business Week Begins21.9.2020 13:00:00 CESTPress release

As the Small Business Administration’s (SBA) National Small Business Week begins in the U.S. and businesses worldwide prepare for an unprecedented holiday season, Visa (NYSE: V) is introducing new programs and resources essential to small and micro business (SMB) recovery efforts. The Visa Back to Business Study, Holiday Edition, launched today, finds that consumers will carry their resolve for normalcy into the holiday shopping season, with 88% planning to buy and give gifts despite challenges the pandemic has created. To prepare for this unprecedented holiday season, SMBs should be looking for ways to offset the impact of COVID-19 during the holidays, with 60% already saying they are taking steps to prepare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005150/en/ Visa’s Back to Business kits include new “tap to pay preferred” point-of-sale materials, branding, educational resources and special offers. (Photo: Busin

"If Agroaceite Grows, Our Communities Grow, Too"21.9.2020 13:00:00 CESTPress release

This is one of our principles at Agroaceite, as pointed out by José Javier Aguirre, Corporate Director of the tropical oil company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005269/en/ Agroaceite's Human Development Center facilities. "Some time ago I had the opportunity to visit Agroaceite ́s medical center, which is managed in collaboration with the University of Colorado. I was pleasantly impressed by the high quality service offered to the surrounding community. This is a good example of the kind of impact that RSPO certification aims to achieve: to improve people’s quality of life within the company ́s area of influence." FRANCISCO NARANJO, RSPO Representative for Latin America. (Photo: Business Wire) "Since Agroaceite was founded, the vision of social responsibility has been clear. Our main asset is our employees, and our best allies are the communities. As Agroaceite succeeds, communities must develop to th

Sagemcom AMI Solution, a Key Driver in the Swedish Energy Transition to a Sustainable Future21.9.2020 10:30:00 CESTPress release

In September, ELLEVIO will continue to improve the Swedish electricity system by being one the first Nordic DSO to start its 2nd generation smart meters large scale rollout. This massive rollout is the result of joint achievements between ELLEVIO, Sagemcom and its local Partner, ONE Nordic. Since the award in March 2019, Sagemcom has developed and delivered a new generation of S211 single phase meters and T211 polyphase meters which allow ELLEVIO to take up the new energy landscape and customer care. The advanced deep indoor dual cellular technology LTE NB IoT + LTE Cat-M is used to secure the reliability of the solution. In less than 8 months and within a specific context, Sagemcom has developed and certified the new generation of smart meters which are installed in the field by ONE Nordic since June 2020 in Stockholm area. The new key features have already been deployed offering a combination of end-user experience - through a customer local interface (P1 Port) - and Low-Voltage netw

Market Failure? kENUP and YUVEDO High-Level Online Event Kick-starts Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases .21.9.2020 10:14:00 CESTPress release

On Friday, 18 September 2020, YUVEDO Foundation and kENUP Foundation held a high-level online conference to kick-start an open public call for projects tackling the growing threat of Parkinson’s (PD) and other neurodegenerative diseases (NDD). Despite the predictable medical, social and economic challengesof NDDs, too little has happened in recent years to address the underlying causes of NDDs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005283/en/ Market and Regulatory Failure? High-Level Online Conference Kick-starts Open Public Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases (Photo: Business Wire) An expert report by Professor Maier-Rigaud of NERA Economic Consulting presented at the conference, showed that there are indications for market and regulatory failure around the development of interventions against PD and other NDDs: High risk in product development is

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom